Literature DB >> 3367488

Rubella antibody persistence after immunization. Sixteen-year follow-up in the Hawaiian Islands.

S Y Chu1, R H Bernier, J A Stewart, K L Herrmann, J R Greenspan, A K Henderson, A P Liang.   

Abstract

A comparative field trial of three rubella virus vaccines (Cendehill, HPV-77 DE-5, and HPV-77 DK-12) was initiated in 1969 on the islands of Kauai and Hawaii in the state of Hawaii. In 1985, follow-up was reinitiated to assess the long-term durability of vaccine-induced immunity. Enzyme-linked immunosorbent assays of serum specimens from 1290 participants demonstrated seropositive rates of 92.4% and 96.4% at screening levels of 10 (protective level) and 7 (lowest detectable level) IU/mL, respectively. The seropositive rates were not related to reinfection or reimmunizations. These findings indicate that vaccine-induced rubella antibodies are detectable in almost all persons up to 16 years after successful vaccination.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3367488     DOI: 10.1001/jama.259.21.3133

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  10 in total

Review 1.  Rubella vaccines: past, present and future.

Authors:  J M Best
Journal:  Epidemiol Infect       Date:  1991-08       Impact factor: 2.451

2.  Increasing rubella seronegativity despite a compulsory school law.

Authors:  T R Schum; D B Nelson; M A Duma; G V Sedmak
Journal:  Am J Public Health       Date:  1990-01       Impact factor: 9.308

Review 3.  The health of adolescent women in the 1980s.

Authors:  I F Litt
Journal:  West J Med       Date:  1988-12

4.  Relationship between HLA polymorphisms and gamma interferon and interleukin-10 cytokine production in healthy individuals after rubella vaccination.

Authors:  Inna G Ovsyannikova; Robert M Jacobson; Jenna E Ryan; Neelam Dhiman; Robert A Vierkant; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2007-01-10

5.  SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine.

Authors:  Neelam Dhiman; Iana H Haralambieva; Richard B Kennedy; Robert A Vierkant; Megan M O'Byrne; Inna G Ovsyannikova; Robert M Jacobson; Gregory A Poland
Journal:  Immunogenetics       Date:  2010-03-10       Impact factor: 2.846

6.  Immunizations in pediatrics: an update.

Authors:  E L Ford-Jones; R Gold
Journal:  Can Fam Physician       Date:  1990-09       Impact factor: 3.275

7.  Rubella antibody screening.

Authors:  K A Redhead; G J Copsey; K Suchak; M Ahmed
Journal:  Br J Gen Pract       Date:  1993-10       Impact factor: 5.386

8.  Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity.

Authors:  Pritish K Tosh; Richard B Kennedy; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

9.  Effect of human leukocyte antigen homozygosity on rubella vaccine-induced humoral and cell-mediated immune responses.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Hum Immunol       Date:  2009-11-05       Impact factor: 2.850

Review 10.  A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.

Authors:  David B Huang; Jashin J Wu; Stephen K Tyring
Journal:  J Infect       Date:  2004-10       Impact factor: 6.072

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.